Quan Anh Vu

Net worth: 272 258 $ as of 30/03/2024

52 year

Health Technology

Consumer Services

Finance

Profile

Quan Anh Vu formerly worked at Baleena Bioscience, Inc., as Chief Executive Officer in 2021, Solganick & Co., Inc., as Managing Director from 2019 to 2021, Opiant Pharmaceuticals, Inc., as Vice President from 2016 to 2019, Ocugen, Inc., as Chief Financial, Accounting & Business Officer in 2023, and 180 Life Sciences Corp., as Chief Operating & Business Officer from 2021 to 2023.
Mr. Vu received his undergraduate degree from the University of California, Los Angeles.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
OCUGEN INC 0.06%	05/03/2023	165,934 ( 0.06% )	272 132 $	30/03/2024
180 LIFE SCIENCES CORP. 0.01%	17/12/2023	54 ( 0.01% )	126 $	30/03/2024

Former positions of Quan Anh Vu

Companies	Position	End
OCUGEN, INC.	Director of Finance/CFO	13/08/2023
180 LIFE SCIENCES CORP.	Chief Operating Officer	17/01/2023
Solganick & Co., Inc.	Corporate Officer/Principal	30/09/2021
Baleena Bioscience, Inc.	Corporate Officer/Principal	30/09/2021
OPIANT PHARMACEUTICALS, INC.	Corporate Officer/Principal	31/07/2019

See the detail of Quan Anh Vu's experience

Training of Quan Anh Vu

University of California, Los Angeles

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Quan Anh Vu's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
OCUGEN, INC.	Health Technology
180 LIFE SCIENCES CORP.	Health Technology

Private companies	3
Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Richmond, VA.	Health Technology
Solganick & Co., Inc.	Finance
Baleena Bioscience, Inc.

See company connections